Stock Movers

Fannie Mae & Freddic Mac IPO Weighed, Gilead Sciences Lifts Outlook, Under Armour Sinks on Weak Sales

Aug 8, 2025
The Trump administration is weighing a potential sale of Fannie Mae and Freddie Mac shares, which could raise around $30 billion and valuate the mortgage giants at $500 billion. Meanwhile, Gilead Sciences boosts its outlook following strong HIV sales, while Under Armour faces challenges with a disappointing sales forecast, raising concerns about its turnaround efforts. Additionally, listeners will enjoy light-hearted commentary on Sweetgreen's stock slide after a controversial menu change.
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Government Weighs Fannie & Freddie Share Sale

  • The Trump administration is considering selling 5–15% of Fannie Mae and Freddie Mac, potentially valuing them near $500 billion.
  • Carol Massar notes both stocks surged roughly 19–21% after reports of the planned offering.
INSIGHT

Gilead Raises Full-Year Outlook

  • Gilead Sciences raised its full-year adjusted EPS guidance to as much as $8.25 after stronger-than-expected HIV drug sales.
  • Carol Massar says the company also lifted product sales guidance by about $100 million, sending stock up over 8%.
INSIGHT

Under Armour Forecasts Worse-Than-Expected Sales

  • Under Armour forecasted Q2 revenue down 6–7%, far below analysts' nearly 3% expected decline.
  • Jess Menton reports the miss stalled the company's turnaround and sent the stock tumbling around 18% or more.
Get the Snipd Podcast app to discover more snips from this episode
Get the app